Bharat Biotech's homegrown COVID-19 vaccine has shown an interim vaccine efficacy of 81% in late-stage clinical trials, the Indian company said on Wednesday.
The interim analysis was based on 43 recorded cases of COVID-19 in the trial of 25,800 participants, conducted in partnership with the Indian government's medical research body.
Thirty-six of the 43 cases were recorded in participants who received a placebo, compared with seven cases in people who were given the Bharat Biotech vaccine, pointing to an efficacy rate of 80.6%, the company said.
India had approved the vaccine, branded COVAXIN, in January without late-stage efficacy data, raising questions about its effectiveness.
India's vaccination drive, currently underway, includes COVAXIN and a vaccine developed by Oxford University and AstraZeneca.
Earlier this week, Indian Prime Minister Narendra Modi was inoculated with the first dose of COVAXIN.
Israel strikes Tehran as Trump says US negotiating to end war
No injuries reported as drone attack hits fuel tank at Kuwait's airport
US expected to send thousands more soldiers to Middle East
Philippines works with Washington to obtain oil from US-sanctioned countries
US safety agency says tracking system failed at LaGuardia during jet collision
Russia fires record 948 drones against Ukraine over 24 hours, Kyiv says
Death toll rises to 69 in Colombian military plane crash
One killed, five injured in Bahrain from Iran strikes
